These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 38317584)

  • 1. Benefits of Implementing Reflex Genomic Analysis for Nonsmall Cell Lung Cancer.
    Smith BF; Hampel KJ; Sidiropoulos N
    J Appl Lab Med; 2024 Jan; 9(1):28-40. PubMed ID: 38167774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of in-house genetic screening for pediatric hearing loss.
    Doerfer KW; Sander T; Konduri GG; Friedland DR; Kerschner JE; Runge CL
    Laryngoscope Investig Otolaryngol; 2020 Jun; 5(3):497-505. PubMed ID: 32596493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer.
    Sridhar A; West HJ; Singhi EK
    Clin Lung Cancer; 2024 Apr; ():. PubMed ID: 38772808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Generalizable Decision-Making Framework for Selecting Onsite versus Send-out Clinical Laboratory Testing.
    Schroeder LF; Rebman P; Kasaie P; Kenu E; Zelner J; Dowdy DW
    Med Decis Making; 2024 Apr; 44(3):307-319. PubMed ID: 38449385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing Next-Generation Sequencing Process Changes to Increase Capacity and Improve Timeliness of Molecular Biomarker Profiling for Lung Cancer Patients.
    Semenuk LJ; Kartolo BA; Feilotter HE; Lee SM; Savage CA; Boag AH; Digby GC; Mates M
    J Appl Lab Med; 2024 Mar; 9(2):284-294. PubMed ID: 38102066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling.
    Salgia R; Mambetsariev I; Tan T; Schwer A; Pearlstein DP; Chehabi H; Baroz A; Fricke J; Pharaon R; Romo H; Waddington T; Babikian R; Buck L; Kulkarni P; Cianfrocca M; Djulbegovic B; Pal SK
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32560187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
    Arbour KC; Riely GJ
    JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations.
    Zhou F; Moreira AL
    Arch Pathol Lab Med; 2016 Dec; 140(12):1331-1337. PubMed ID: 27588333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.
    Grafham GK; Craddock KJ; Huang WY; Louie AV; Zhang L; Hwang DM; Parmar A
    Cancer Med; 2024 Feb; 13(3):e6886. PubMed ID: 38317584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.
    DiStasio M; Chen Y; Rangachari D; Costa DB; Heher YK; VanderLaan PA
    Clin Lung Cancer; 2017 Sep; 18(5):e349-e356. PubMed ID: 28377205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
    Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
    Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
    Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
    Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre.
    Fleming KE; Hupel A; Mithoowani H; Lulic-Kuryllo T; Valdes M
    Curr Oncol; 2024 Mar; 31(3):1515-1528. PubMed ID: 38534948
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.